Astrazeneca (AZN) Return on Sales (2009 - 2026)

Astrazeneca (AZN) has reported Return on Sales for 18 consecutive years, with 0.11% the latest figure, recorded in Q1 2026.

• In Q1 2026, Return on Sales rose 19.0% year-over-year to 0.11%; the TTM figure through Mar 2026 stood at 0.09% (up 10.0% YoY), while the FY2025 annual figure was 0.0%, down 7.0% from the prior year.
• Return on Sales came in at 0.11% for Q1 2026 at Astrazeneca, up from 0.25% in the prior quarter.
• The five-year high for Return on Sales was 4.89% in Q2 2022, with the low at 0.54% in Q2 2025.
• Average Return on Sales over 5 years is 0.34%, with a median of 0.01% recorded in 2022.
• Across the five-year window, Return on Sales surged 491 bps in 2022 and plunged 487 bps in 2023, its largest moves.
• Year by year, Return on Sales stood at 0.06% in 2022, then jumped by 46 bps to 0.03% in 2023, then surged by 106 bps to 0.0% in 2024, then slumped by 12374 bps to 0.25% in 2025, then soared by 143 bps to 0.11% in 2026.
• According to Business Quant data, Return on Sales over the past three periods registered 0.11%, 0.25%, and 0.61% for Q1 2026, Q4 2025, and Q3 2025 respectively.